ProTargetMiner

ProTargetMiner provides a proteome signature library and analytical framework to deconvolute targets and mechanisms of action for anticancer compounds.

Key Features:

• Proteome Signature Library: Compiles proteomic data from 287 A549 adenocarcinoma cell line proteomes treated with 56 compounds, comprising 7,328 proteins and 1,307,859 refined protein-drug pairs organized by compound targets and action mechanisms.
• Mechanism Deconvolution: Employs partial least square modeling to identify target and mechanistic proteins associated with each compound.
• Cross-cell Line Analysis: Integrates deep proteome datasets from three cancer cell lines—MCF-7, RKO, and A549—to reveal shared and cell-specific drug responses.
• Expandable Database: Designed to incorporate additional compound proteome signatures to extend the signature library and pairwise dataset.

Scientific Applications:

• Target Identification: Analyze proteomic signatures to identify novel drug targets.
• Mechanism Elucidation: Determine mechanisms of action of anticancer compounds through protein-level associations.
• Cross-cell-line Comparison: Compare cellular proteomic responses across MCF-7, RKO, and A549 to distinguish universal versus cell-specific drug effects.

Methodology:

Collection and refinement of proteome data from treated cancer cell lines (including 287 A549 proteomes from 56 compounds yielding 7,328 proteins and 1,307,859 protein-drug pairs), integration of deep proteome datasets from MCF-7, RKO, and A549, and partial least square modeling to deconvolute drug-target and mechanism associations.